RxDoctor Payments Data

Hsiao Lai, MD

Nephrology · Greenville, NCNPI 1285841379

Payments from drug & device makers

$1,487in general payments, 2019–2025

Across 72 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$270
  • Vifor Pharma, Inc.$235
  • Recor Medical Inc$184
  • Aurinia Pharma U.S., Inc.$136
  • Bayer$124
  • Mallinckrodt Hospital Products Inc.$114
  • plus $424 from 9 others

What the payments were for

  • Food & beverage$1,38193%
  • Education$1067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,487 in reported general payments places this provider in the 50th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,281
Medicare patients
145
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$31,053
AuryxiaFerric Citrate14$30,853
FarxigaDapagliflozin Propanediol20$17,263
KerendiaFinerenone13$8,102
Sevelamer Carbonate34$6,381
XareltoRivaroxaban12$6,268
Bumetanide48$2,820
Potassium Citrate ErPotassium Citrate18$2,678
Methenamine Hippurate23$1,409
Calcitriol30$786
Torsemide14$508
Amlodipine Besylate44$409
Midodrine Hcl12$397
Valsartan19$336
Furosemide82$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$41$30,85314 claims
AstraZenecaFarxiga$270$17,26320 claims
BayerKerendia$124$8,10213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →